Program Indication Research Preclinical Phase 1 Phase 2 Phase 3
ATYR1923 Pulmonary Sarcoidosis


Other ILDs (CTD-ILD; CHP)(1)


Healthy Japanese Volunteers(2)


COVID-19 related severe respiratory complications


ATYR2810 Solid Tumors


NRP2 mAbs Cancer; Inflammation


tRNA Synthetase Candidates Immunology;(3) Cancer; Fibrosis


Program Target Phase
ATYR1923 Pulmonary Sarcoidosis Phase 2
Other ILDs (CTD-ILD; CHP)1 Phase 1
Healthy Japanese Volunteers2 Phase 1
COVID-19 related severe respiratory complications Phase 3
ATYR2810 Solid Tumors Preclinical
NRP2 mAbs Cancer; Inflammation Research
tRNA Synthetase Programs Immunology;3Cancer; Fibrosis Research

(1) CTD-ILD: connective tissue disease-related ILD (e.g. Scleroderma-related ILD); CHP: chronic hypersensitivity pneumonitis
(2) In partnership with Kyorin Pharmaceutical Co., Ltd.
(3) Includes research collaboration with CSL Behring, Ltd